53
Views
0
CrossRef citations to date
0
Altmetric
Pulmonary Medicine

Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma

, , , ORCID Icon, , , , & show all
Article: 2382377 | Received 04 Oct 2023, Accepted 17 May 2024, Published online: 25 Jul 2024

References

  • Global Strategy for Asthma Management and Prevention (GINA) 2018. Global Strategy for Asthma Management and Prevention (2017 update). Vol. 135; 2018. Retrieved from www.ginasthma.org.
  • Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention at Online Appendix. Vol. 89; 2016.
  • Soto-Martínez ME, Soto-Quiros ME, Custovic A. Childhood asthma: low and middle-income countries perspective. Acta Med Acad. 2020;49(2):181–190. doi: 10.5644/ama2006-124.296.
  • Global initiative for Asthma. Global strategy for asthma management and prevention; 2023. Available from:www.ginaasthma.org.
  • Wang Z, Li Y, Gao Y, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res. 2023;24(1):169. doi: 10.1186/s12931-023-02475-6.
  • Demoly P, Annunziata K, Gubba E, et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. doi: 10.1183/09059180.00008111.
  • Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16(5):802–807. doi: 10.1183/09031936.00.16580200.
  • George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51. doi: 10.1177/2040622315609251.
  • Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–1039. doi: 10.1056/NEJM199010113231505.
  • Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721. doi: 10.1016/S0140-6736(02)11679-5.
  • Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbation. Eur Respir J. 2006;27(3):483–494. doi: 10.1183/09031936.06.00137704.
  • Ulrik CS, Lange P, Hilberg O. Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: a systematic review. Eur Clin Respir J. 2021;8(1):1891725. doi: 10.1080/20018525.2021.1891725.
  • Louis R, Schleich F, Barnes PJ. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med. 2012;33(3):531–541. doi: 10.1016/j.ccm.2012.05.004.
  • Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108. doi: 10.1183/09031936.00201813.
  • Mallah N, Rodriguez-Segade S, Gonzalez-Barcala F-J, Takkouche B. Blood eosinophil count as predictor of asthma exacerbation: a meta-analysis. Pediatr Allergy Immunol. 2021;32(3):465–478.
  • ten Brinke A, de Lange C, Zwinderman AH, et al. Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med. 2001;164(5):749–753. doi: 10.1164/ajrccm.164.5.2009035.
  • Gustafsson LE, Leone AM, Persson MG, et al. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun. 1991;181(2):852–857. doi: 10.1016/0006-291x(91)91268-h.
  • Neelamegan R, Saka V, Tamilarasu K, et al. Clinical utility of fractional exhaled nitric oxide (FeNO) as a biomarker to predict severity of disease and response to inhaled corticosteroid (ICS) in asthma patients. J Clin Diagn Res. 2016;10(12):1.
  • Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. doi: 10.1183/13993003.01633-2019.
  • Heffler E, Carpagnano GE, Favero E, et al. Fractional exhaled nitric oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Multidiscip Respir Med. 2020;15(1):36. doi: 10.4081/mrm.2020.36.
  • Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67(3):199–208. doi: 10.1136/thx.2010.135574.
  • Honkoop PJ, Loijmans RJ, Termeer EH, Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group, et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol. 2015;135(3):682–688.e11. doi: 10.1016/j.jaci.2014.07.016.
  • Nguyen VN, Chavannes NH. Correlation between fractional exhaled nitric oxide and asthma control test score and spirometry parameters in on-treatment-asthmatics in Ho Chi Minh City. J Thorac Dis. 2020;12(5):2197–2209. doi: 10.21037/jtd.2020.04.01.
  • Katoch CDS, Vasan AS, Pathak K. Correlation of fraction of exhaled nitric oxide with asthma control test and asthma severity in diagnosed cases of asthma. Med J Armed Forces India. 2022;78(4):443–447. doi: 10.1016/j.mjafi.2021.01.018.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: Global Initiative for Chronic Obstructive Pulmonary Disease; 2010.
  • Perzanowski MS, Yoo Y. Exhaled nitric oxide and airway hyperresponsiveness to adenosine 5'-monophosphate and methacholine in children with asthma. Int Arch Allergy Immunol. 2015;166(2):107–113. doi: 10.1159/000375237.
  • Dweik RA, Boggs PB, Erzurum SC, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi: 10.1164/rccm.9120-11ST.
  • Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi: 10.1016/j.jaci.2003.09.008.
  • Majellano EC, Clark VL, Winter NA, et al. Approaches to the assessment of severe asthma: barriers and strategies. J Asthma Allergy. 2019;12:235–251. doi: 10.2147/JAA.S178927.
  • Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6(9):1368–1370. doi: 10.1183/09031936.93.06091368.
  • Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–1008. doi: 10.1164/ajrccm.160.3.9812110.
  • Mogensen I, Alving K, Jacinto T, et al. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007–12. Clin Exp Allergy. 2018;48(8):935–943. doi: 10.1111/cea.13137.
  • Gao J, Chen Z, Jie X, et al. Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma. J Asthma Allergy. 2018;11:73–79. doi: 10.2147/JAA.S155379.
  • Truong-Thanh T, Vo-Thi-Kim A, Vu-Minh T, et al. The beneficial role of FeNO in association with GINA guidelines for titration of inhaled corticosteroids in adult asthma: a randomized study. Adv Med Sci. 2020;65(2):244–251. doi: 10.1016/j.advms.2020.03.001.
  • Meltzer EO, Busse WW, Wenzel SE, et al. Use of the asthma control questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol. 2011;127(1):167–172. doi: 10.1016/j.jaci.2010.08.042.
  • Mphahlele RE, Kitchin O, Masekela R. Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review. BMJ Open. 2021;11(10):e053100. doi: 10.1136/bmjopen-2021-053100.
  • Feng JX, Lin Y, Lin J, et al. Relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma–COPD overlap syndrome patients with different disease severity. J Kor Med Sci. 2017;32(3):439–447. doi: 10.3346/jkms.2017.32.3.439.
  • Kriti CY, Mohapatra AK, Manu MK, et al. Comparison of fractional exhaled nitric oxide, spirometry, and asthma control test, in predicting asthma exacerbations: a prospective cohort study. Lung India. 2020;37(5):394–399. doi: 10.4103/lungindia.lungindia_546_19.
  • Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax. 2015;70(6):543–550. doi: 10.1136/thoraxjnl-2014-206161.
  • Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008;372(9643):1065–1072. doi: 10.1016/S0140-6736(08)61448-8.
  • Al Ghobain MO, Alsubaie AS, Aljumah WA, et al. The correlation between fractional exhaled nitric oxide (FeNO), blood eosinophil count, immunoglobulin E levels, and spirometric values in patients with asthma. Cureus. 2023;15(2):e35289. doi: 10.7759/cureus.35289.
  • Lommatzsch M, Klein M, Stoll P, et al. Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma. Allergy. 2021;76(10):3199–3202. doi: 10.1111/all.14997.
  • Moeller A, Carlsen KH, Sly PD, ERS Task Force Monitoring Asthma in Children, et al. Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation. Eur Respir Rev. 2015;24(136):204–215. doi: 10.1183/16000617.00003914.
  • Badar A, Salem AM, Bamosa AO, et al. Association between FeNO, total blood IgE, peripheral blood eosinophil and inflammatory cytokines in partly controlled asthma. JAA. 2020;13:533–543. doi: 10.2147/JAA.S274022.